Trial Profile
Phase I, Open-Label, Pharmacokinetic, Safety and Tolerability Study of Subcutaneously Administered Bisphosphonate With Recombinant Human Hyaluronidase (rHuPH20) vs Bisphosphonate.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Hyaluronidase (Primary) ; Bisphosphonates
- Indications Osteoporosis
- Focus Adverse reactions
- Sponsors Halozyme Therapeutics
- 13 Aug 2018 Status changed from active, no longer recruiting to completed.
- 16 Jun 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 02 Jan 2009 New trial record.